A Phase 1 interventional study of CHF10136 and CHF10136 matched placebo in Asthma and Healthy Volunteers, sponsored by Chiesi Farmaceutici S.p.A.. Recruiting at 3 sites in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..
Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 29th largest by planned enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2026, is one of 9 in phase 1, reaches primary completion later than 7 of the 10 other live ones, and was the 80th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:
Chiesi Farmaceutici S.p.A. · Sites in Bulgaria
Ages 18+
Chiesi Farmaceutici S.p.A. · Sites in China
Ages 18–75
Chiesi Farmaceutici S.p.A. · Sites in Argentina, Bosnia and Herzegovina, Bulgaria and 11 more countries
Ages 18–75
Chiesi Pharma AB, Nordic · Sites in Denmark
Ages 18+
Chiesi Slovenija, d.o.o. · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 28 · Phase 3 24 · Phase 4 4
First in 2002; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 97 across the 66 interventional studies, 300 across the 15 observational. Of the 69 that completed or were terminated, 13 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
2 of the studies in Asthma by Chiesi Farmaceutici S.p.A. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07301736Chiesi Farmaceutici S.p.A.Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma | 2027-06-03 |
| NCT06908421Chiesi Pharma AB, NordicEfficacy of a Smart add-on Device in Combination With a Triple Treatment in Asthma Patients on Inhaler Technique and Adherence | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the safety and tolerability of CHF10136 administered by inhalation in healthy adults and adults with asthma. The study includes single-dose, multiple-dose, and repeated-dose treatment periods and will also characterize the pharmacokinetic profile of CHF10136.
This is a first-in-human (FiH), randomized, double-blind, placebo-controlled study of CHF10136 administered via dry powder inhaler.
The study consists of three sequential parts. Part 1 is a single ascending dose evaluation in healthy adult participants. Part 2 is a multiple ascending dose evaluation in participants with mild asthma. Part 3 is a repeated-dose evaluation in participants with moderate-to-severe asthma. Dose escalation and progression between study parts will occur following review of available safety and pharmacokinetic data.
Healthy participants and participants with asthma will be enrolled and randomized to receive CHF10136 or placebo. Safety assessments, pharmacokinetic sampling, and exploratory pharmacodynamic assessments will be performed throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For PART 1 - SAD
For PART 2 - MAD
For PART 3 - REPEATED DOSE
EXCLUSION CRITERIA:
For PART 1 - SAD
For PART 2 - MAD
For PART 3 - REPEATED DOSE
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive CHF10136 administered via dry powder inhaler. Doses vary according to study cohort.
Drug: CHF10136
Participants receive placebo powder for inhalation administered via dry powder inhaler.
Drug: CHF10136 matched placebo
CHF10136 powder for inhalation administered orally using a Dry Powder Inhaler.
Matching placebo powder for inhalation administered using a Dry Powder Inhaler.
Number of Participants With Treatment-Emergent Adverse Events
Assessment of safety through collection of treatment-emergent adverse events.
Time frame: Part 1, 2 and 3: Day - 28 to Day - 2 (Screening Visit), Day -1, Day 1, Day 2, Day 3, Day 4, and Day 8 (Follow-up Visit)
Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure
Time frame: Part 1, 2 and 3:Day - 28 to Day - 2 (Screening Visit), Day -1, Day 1, Day 2, Day 3, Day 4, and Day 8 (Follow-up Visit)
Change From Baseline in Electrocardiogram Parameters: HR (Heart Rate)
Time frame: Part 1, 2 and 3:Day - 28 to Day - 2 (Screening Visit), Day -1, Day 1, Day 2, Day 3, Day 4, and Day 8 (Follow-up Visit)
Change From Baseline in Electrocardiogram Parameters: Intervals recorded: PR, QT, QRS duration, QTcF (Fridericia corrected QT interval)
Time frame: Part 1: Day 1 to Day 2 - Part 2 & 3: Day 1 to Day N + 1 (Day after the last treatment intake)
Change From Baseline in Clinical Laboratory Parameters
Number of subjects with abnormal blood laboratory test results. Quantitative laboratory parameters (chemistry and haematology) will be summarised by treatment as absolute value and change from baseline using descriptive statistics. Number of subjects with abnormal urine laboratory test results.
Time frame: Part 1: Screening visit, Day -1, Day 4 and Day 8 - Part 2 & 3: Screening Visit, Day -1, Day 4 , Day 7, Day N+1 (Day after the last treatment intake), Day N+7 (Follow-up Visit)
Change From Baseline in Forced Expiratory Volume in One Second (FEV1)
Time frame: Part 1: Screening Visit, Day 1 and Day 2 - Part 2& 3: Screening Visit, Day -1, Day 1 and Day N (the last day of treatment intake)
Area Under the Plasma Concentration-Time Curve (AUC) for CHF10136 (parent compound) and its main metabolite.)
Time frame: Part 1: Up to 72 hours post-dose and on Day 1 - Part 2 & 3: Day N (the last day of treatment intake )
Maximum Observed Plasma Concentration (Cmax) of CHF10136 (parent compound) and its main metabolite.)
Time frame: Part 1: on Day 1, up to 72 hours post-dose - Part 2 & 3: on Day 1 and Day N (the last day of treatment intake )
Time to Maximum Plasma Concentration (Tmax) of CHF10136 (parent compound) and its main metabolite.)
Time frame: Part 1: on Day 1, up to 72 hours post-dose - Part 2 & 3: on Day 1 and Day N (the last day of treatment intake )
Terminal Half-Life (t½) of CHF10136 (parent compound) and its main metabolite.)
Time frame: Day 1 for Part 1
Apparent Clearance (CL/F) of CHF10136 (parent compound) and its main metabolite.)
Time frame: Up to 72 hours post-dose
Apparent Volume of Distribution (Vz/F) of CHF10136 (parent compound) and its main metabolite.)
Time frame: Up to 72 hours post-dose
Pharmacokinetic Parameters of the main Metabolite
includes AUC
Time frame: Up to 72 hours post-dose
Pharmacokinetic Parameters of the main Metabolite
includes Cmax
Time frame: Up to 72 hours post-dose
Pharmacokinetic Parameters of the main Metabolite
include Metabolite Ratios
Time frame: Up to 72 hours post-dose
Plan to share: No — Chiesi clinical data sharing scope, process and data access criteria is available on the Chiesi Group website
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Dec 2027, 14 months after the start.
Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 14 months is above that.
Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.